SEPN Septerna, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1984086 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY336.7%
TTM net income YoY-0.3%
TTM EPS YoY-109.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-76.2%
Net margin-61.3%
FCF margin-80.6%
EBITDA margin-74.6%
Returns
ROE-14.4%
ROA-9.6%
ROIC (approx.)-35.2%
Asset turnover0.16x
Leverage & solvency
Liabilities / assets30.9%
Debt / equity0.00x
Current ratio4.84x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.30x
Accruals ratio2.9%
Payout ratio—
Capex / revenue1.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $18.88M | $26.75M | $26.52M | $24.12M | $21.50M | $119,000 | $219,000 | $212,000 |
| R&D expense | $36.56M | $35.13M | $29.54M | $31.86M | $24.26M | $22.19M | $19.27M | $19.32M |
| SG&A expense | $9.55M | $8.45M | $10.29M | $8.28M | $7.12M | $6.91M | $6.86M | $5.61M |
| Operating income | -$27.23M | -$16.84M | -$13.30M | -$16.02M | $2.61M | -$28.98M | -$25.91M | -$24.72M |
| Pretax income | -$21.97M | -$12.06M | -$8.30M | -$10.73M | $8.17M | -$24.84M | -$21.48M | -$20.83M |
| Income tax | $4.62M | $973,000 | $337,000 | $12,000 | $0 | $0 | $0 | -$160,000 |
| Net income | -$26.59M | -$13.03M | -$8.64M | -$10.74M | $8.17M | -$24.84M | -$21.48M | -$20.67M |
| EBITDA | -$26.83M | -$16.44M | -$12.90M | -$15.62M | $3.01M | -$28.58M | -$25.51M | -$24.32M |
| EPS (basic) | -0.57 | -0.29 | -0.19 | — | 0.18 | -0.56 | -0.49 | — |
| EPS (diluted) | -0.57 | -0.29 | -0.19 | — | 0.18 | -0.56 | -0.49 | — |
| Weighted avg. shares (diluted) | 46.91M | 45.04M | 44.76M | — | 45.60M | 44.17M | 43.94M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $167.12M | $84.66M | $71.61M | $120.72M | $319.99M | $189.31M | $210.04M | $238.20M |
| Short-term investments | $311.48M | $287.66M | $275.80M | $270.37M | $154.36M | $137.25M | $125.96M | $112.73M |
| Receivables | $18.88M | $12.16M | $10.84M | $10.36M | $8.64M | $151,000 | $250,000 | $171,000 |
| Current assets | $507.35M | $396.15M | $368.06M | $410.96M | $491.68M | $334.14M | $342.47M | $356.82M |
| PP&E, net | $3.83M | $3.90M | $4.33M | $4.43M | $4.32M | $4.69M | $5.04M | $5.09M |
| Total assets | $619.40M | $566.74M | $569.69M | $596.19M | $606.65M | $415.23M | $434.02M | $456.55M |
| Current liabilities | $104.86M | $79.32M | $78.17M | $86.93M | $75.28M | $15.13M | $10.64M | $12.85M |
| Total liabilities | $191.47M | $180.02M | $191.23M | $214.26M | $217.92M | $37.67M | $33.75M | $36.51M |
| Shareholders' equity | $427.93M | $386.72M | $378.46M | $381.93M | $388.73M | $377.56M | $400.27M | $420.05M |
| Shares outstanding | 47.41M | 45.67M | 44.92M | 44.81M | 44.64M | 44.57M | 44.45M | 44.42M |
| Cash flow statement | ||||||||
| Operating cash flow | -$13.77M | -$22.18M | -$25.63M | -$14.99M | $168.81M | -$20.29M | -$23.34M | -$20.96M |
| Capital expenditure | $127,000 | $0 | $832,000 | $65,000 | $13,000 | $58,000 | $382,000 | $612,000 |
| Free cash flow | -$13.89M | -$22.18M | -$26.46M | -$15.05M | $168.79M | -$20.34M | -$23.73M | -$21.57M |
| Investing cash flow | $33.48M | $18.41M | -$23.82M | -$185.30M | -$38.39M | -$786,000 | -$4.87M | -$133.24M |
| Financing cash flow | $62.75M | $16.82M | $333,000 | $1.02M | $263,000 | $339,000 | $66,000 | $304.15M |
| Depreciation & amortization | $400,000 | $400,000 | $400,000 | $400,000 | $400,000 | $400,000 | $400,000 | $400,000 |
| Stock-based compensation | $5.92M | $5.07M | $6.01M | $2.66M | $2.53M | $1.81M | $1.48M | $1.26M |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.